최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Clinical lymphoma, myeloma & leukemia, v.15 no.4, 2015년, pp.199 - 207
This systematic literature review with meta-analysis was conducted on the clinical efficacy and safety of interventions used in the treatment of chronic lymphocytic leukemia (CLL). We systematically searched databases (PubMed, Cochrane Library, and Embase; 1997 to August 2, 2012), conference abstrac...
National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer Statistics Review: 1975-2010. Available at: http://seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_13_leukemia.pdf. Accessed November 21, 2013.
American Cancer Society. What are the key statistics for chronic lymphocytic leukemia? Available at: http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf. Accessed May 14, 2014.
J Clin Oncol Harris 17 3835 1999 10.1200/JCO.1999.17.12.3835 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
Cancer Manag Res Chao 5 251 2013 10.2147/CMAR.S34273 Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies
N Engl J Med Rai 343 1750 2000 10.1056/NEJM200012143432402 Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
Expert Rev Anticancer Ther Molica 11 1333 2011 10.1586/era.11.118 Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial
NICE. National Institute for Health and Care Excellence. Specification for manufacturer/sponsor submission of evidence. Available at: http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf. Accessed March 20, 2013.
Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. Available at: http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed March 20, 2013.
J Clin Epidemiol Bucher 50 683 1997 10.1016/S0895-4356(97)00049-8 The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
Br J Haematol Robak 108 357 2000 10.1046/j.1365-2141.2000.01850.x Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients
Haematologica Robak 90 994 2005 The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil
Clinicaltrials.gov [Web site]. Efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL). Available at: http://clinicaltrials.gov/ct2/show/NCT00802737?term=NCT00802737&rank=1. Accessed July 17, 2013.
J Clin Oncol O'Brien 25 1114 2007 10.1200/JCO.2006.07.1191 Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Lancet Oncol Elter 12 1204 2011 10.1016/S1470-2045(11)70242-X Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial
Cancer Faderl 107 916 2006 10.1002/cncr.22097 Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia
Br J Haematol Hillmen 152 570 2011 10.1111/j.1365-2141.2010.08317.x A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
J Clin Oncol O'Brien 27 5208 2009 10.1200/JCO.2009.22.5748 Five-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen
J Clin Oncol Robak 28 1756 2010 10.1200/JCO.2009.26.4556 Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia
10.1182/blood.V118.21.2859.2859 Wendtner C, Fraser G, Goldberg S, et al. Interim results for the safety and efficacy of different lenalidomide starting dose regimens in subjects with relapsed or refractory chronic lymphocytic leukemia (CC-5013-CLL-009 Study). Presented at the 2011 ASH annual meeting; December 11, 2011. San Diego, CA.
Blood Cheson 87 4990 1996 10.1182/blood.V87.12.4990.bloodjournal87124990 National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
FDA. US Food and Drug Administration. FDA News Release: FDA approves Imbruvica to treat chronic lymphocytic leukemia. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm385764.htm. Accessed May 16, 2014.
Gilead Sciences. US FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin's Lymphoma. Available at: http://www.gilead.com/news/press-releases/2014/1/us-fda-accepts-new-drug-application-for-gileads-idelalisib-for-the-treatment-of-refractory-indolent-nonhodgkins-lymphoma. Accessed May 16, 2014.
Ann Oncol Eichhorst 22 suppl 6 vi50 2011 10.1093/annonc/mdr377 Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Clin Oncol Fischer 29 3559 2011 10.1200/JCO.2010.33.8061 Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
10.1200/jco.2013.31.15_suppl.7003 Brown JR, Furman RR, Flinn I, et al. Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL. Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.
10.1200/jco.2013.31.15_suppl.tps8614 Salles GA, Gopal AK, Martin P, et al. An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. Presented at the Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.
10.1200/jco.2013.31.15_suppl.tps8619 Byrd JC, Barrientos JC, Devereux S, et al. A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE. Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); May 31-June 4, 2013. Chicago, IL.
J Clin Oncol Byrd 32 5s 2014 10.1200/jco.2014.32.15_suppl.lba7008 Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase III RESONATE trial
10.1182/blood.V122.21.871.871 Flynn JM, Andritsos LA, Jones JA, et al. Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Presented at the 55th ASH Annual Meeting and Exposition, December 4-10, 2013. New Orleans, LA.
J Clin Oncol Gladstone 32 2014 10.1200/jco.2014.32.15_suppl.3028 Phase 2 open-lable study of MEDI-551 and bendamustine versus rituximab and bendamusting in adults with relapsed or refractory CLL
J Clin Oncol Sharman 32 5s 2014 10.1200/jco.2014.32.15_suppl.7007 Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia
J Clin Oncol Seymour 32 5s 2014 10.1200/jco.2014.32.15_suppl.7015 ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic keukemia (CLL) and small lymphocytic lymphoma (SLL): high complete-response rate and durable disease control
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.